Ortiz NDA, Hernández MI, Ayala AR

Idioma: Español
Referencias bibliográficas: 23
Paginas: 315-327
Archivo PDF: 92.46 Kb.

RESUMEN

Las características del ovario poliquístico son: anovulación, hiperandrogenemia y resistencia a la insulina. La relación entre hiperinsulinemia y enfermedad cardiovascular es bien conocida, así como el riesgo de resultar con diabetes mellitus. La resistencia a la insulina desempeña un papel importante en la patogénesis del ovario poliquístico y, por esto, se permite el uso de medicamentos sensibilizadores a la insulina. En la última década se han diseñado diversos estudios acerca del uso de estos fármacos en el ovario poliquístico, lo que favorece su recomendación clínica. El tratamiento del ovario poliquístico incluye objetivos de atención a corto plazo, como el de infertilidad y control del exceso de andrógenos, así como a largo plazo prevenir el cáncer de endometrio y tratar el síndrome dismetabólico con su respectivo riesgo de diabetes mellitus tipo 2 y enfermedad cardiovascular. Esta revisión justifica el uso racional de los medicamentos sensibilizadores a insulina para tratar ambos objetivos de manera exitosa en el ovario poliquístico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Centeno A, Hernández I, Mendoza R, et al. Ovarios poliquísticos: expresión clínica y bioquímica. Ginecol Obstet Mex 2003;71:253-8.

2. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocrin Rev 2003;24:633-67.

3. Yann R, Frederique D, Loic G, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computarized quantification. Fertil Steril 1995;64:307-12.

4. Taylor A, McCourt B, Martin K. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-53.

5. Apter D, Butzow T, Laughlin G. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995;80:2966-71.

6. Nelson V, Qin K, Rosenfield R, Wood J, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925-33.

7. Wickenheisser J, Quinn P, Nelson V, et al. Differential activity of the cytochrome P450 17ahydroxilase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2000;85:2304-11.

8. Elting M, Korsen T, Rekers-Mombarg L, et al. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-28.

9. Wang J, Davies M, Norman R. Polycystic ovary syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-9.

10. Holte J, Gennarelli G, Wide L, et al. High prevalence of polycystic and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-50.

11. Rajkhowa M, Neary R, Kumpatla P. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-94.

12. Atiomo W, Bates S, Condon J, et al. The plasminogen activator system in women with polycystic ovary syndrome Fertil Steril 1998;69:236-41.

13. Cheung A. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-31.

14. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.

15. Pellicer A, Simón C. Cuadernos de medicina reproductiva. Hiperandrogenismos. 1ª ed. Madrid: Panamericana,1996.

16. Katz A, Nambi S, Mather K, et al. Quantitative insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.

17. Barbieri R. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000;183:1412-8.

18. Ching W, Yap C, Sian A. Clinical management of PCOS. Acta Obstet Gynaecol Scand 2001;80:689-96.

19. Ibañez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002;87:5702-5.

20. Costello M, Eden J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13.

21. Ibañez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-8.

22. Nestler J, Jakubowicz D, Evans W, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.

23. Heard M, Pierce A, Carson S, et al. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:669-73.